Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Compass Therapeutics. The associated price target was raised to $12.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Charles Zhu has given his Buy rating due to a combination of factors tied to Compass Therapeutics’ advancing clinical pipeline and growing evidence of efficacy. He highlights the confirmation of a third clinical response to CTX-8371, now observed in Hodgkin lymphoma, as an important signal that reinforces the drug’s potential across multiple tumor types. Zhu also points to the upcoming data from the COMPANION-002 study, which remain on schedule for release in late first quarter 2026, as a key value-creating catalyst. Together, these elements support his view that Compass is executing well and that its lead asset could meaningfully differentiate in the immuno-oncology landscape.
In addition, Zhu notes that management’s recent corporate update outlines a clear roadmap heading into a busy 2026, with several clinical events that could further validate the platform. He believes this visibility into near-term milestones, combined with current valuation levels, offers an attractive risk-reward profile for investors. Reflecting this confidence, he raises his price target to $12 and maintains an Outperform (Buy) rating, suggesting meaningful upside from current trading levels. Overall, Zhu’s stance is that the strengthening clinical dataset and well-defined development trajectory justify a constructive, long-term view on the stock.
In another report released on January 8, Canaccord Genuity also maintained a Buy rating on the stock with a $10.00 price target.